medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Number 2

<< Back Next >>

Ann Hepatol 2004; 3 (2)

Experimental models for hepatitis C virus (HCV): New opportunities for combating hepatitis C

Trujillo-Murillo KC, Garza-Rodríguez ML, Martínez-Rodríguez HG, Barrera-Saldaña HA, Bosques-Padilla F, Ramos-Jiménez J, Rivas-Estilla AM

Language: English
References: 76
Page: 54-62
PDF size: 118.00 Kb.


Text Extraction

Infection with hepatitis C virus (HCV) is a global public health issue. More than 200 million people in the world are infected with HCV. Hepatitis C is considered one of the main causes of chronic hepatitis, cirrhosis, hepatocellular carcinoma and liver transplantation. The identification of the viral genome quickly allowed delineation of genomic organization, and the structure and biochemical characterization of the proteins of HCV. However, it has been difficult to study its life cycle, as well as the development of antiviral agents due to the lack of a system of permissible culture. Numerous attempts have been reported to establish an in vitro system for the study of HCV. Recently, a system of efficient culture was established that allows replication of subgenomic molecules of HCV in a cell line of human hepatoma. In this revision, after a brief description of the molecular biology, means of transmission and clinical characteristics of hepatitis C, some of the experimental models are described that have been developed to date, focusing mainly on the subgenomic replicon system and their use in the development of new antiviral treatments.


REFERENCES

  1. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-2100.

  2. Montaño-Loza A, Meza-Junco J, Remes-Troche JM. Patogénesis de la infección por virus de hepatitis C. Rev Invest Clin 2001; 53: 561-568.

  3. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. Gastroenterology 2002; 6: 2082-2099.

  4. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19.

  5. Aguilar-Ramírez JR, Aguirre-García J, Bautista-González H, Baptista-González H, Bosques-Padilla FJ, Campollo-Rivas O, Contreras AM, et al. Consenso Nacional sobre Hepatitis C. Rev Invest Clin 2002; 54: 559-568.

  6. Rivas-Estilla AM, Panduro A. Mecanismos moleculares del virus de la hepatitis C, potenciales blancos terapéuticos. Rev Invest Clin 2003; 55: 51-64.

  7. Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A, Dehesa M, Juárez A, Castañeda B, Sánchez-Ávila F, et al. Etiology of Liver Cirrhosis in Mexico. Annals of Hepatology 2004; 3: 30-33.

  8. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl Med 2001; 1: 41-52.

  9. Valladares-Álvarez G. Factores de riesgo para la progresión de la infección crónica de la hepatitis viral C. Gastroenterol Perú 2003; 23: 126-133.

  10. World Health Organization. Weekly Epidemiological Record 2002; 77: 41-48.

  11. Choo QL, Kuo GF, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.

  12. Rivas-Estilla AM, Sánchez LV, Matsui O, Campollo O, Armendáriz-Borunda J, Segura-Ortega JE, Panduro A. Identification of hepatitis C virus (HVC) genotypes in infected patients from the west of Mexico. Hepatology Research 1998; 12: 121-130.

  13. Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O, Cortez-Hernández C, Dehesa-Violante M, Maldonado-Garza H, Pérez-Gómez R, et al. Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology 2003; 2: 135-139.

  14. Bartenschlager R, Lohmann V. Novel cell culture systems for the hepatitis C virus. Antiviral Research 2001; 52: 1-17.

  15. Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a virus like antigen associated with acute illness. Science 1973; 182: 1026-1028.

  16. He LF, Alling DF, Popkin TF, Shapiro M, Alter HJ, Purcell RH. Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis 1987; 156: 636-640.

  17. Bartenschlager R, Lohmann V. Replication of the hepatitis C virus. J Gen Virol 2000; 81; 1631-1648.

  18. Ohba K, Mizokami M, Lau JY, Orito E, Ikeo K, Gojoborit T. Evolutionary relationship of hepatitis C, pesti-, flavi-, plant-, viruses, and newly discovered GB hepatitis agents. FEBS Lett 1996; 378: 232-234.

  19. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line. Science 1999; 285: 110-113.

  20. Puig-Basagoiti F, Sáiz JC. Replicones subgenómicos del virus de la hepatitis C (VHC): nuevas expectativas para la profilaxis y el tratamiento de la hepatitis C. Gastroenterol Hepatol 2001; 24: 506-510.

  21. Drazan KE. Molecular Biology of Hepatitis C Infection. Liver Transplantation 2000; 6: 396-406.

  22. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 2001; 313: 451-464.

  23. Friebe P, Lohmann VF, Krieger NF, Bartenschlager R. Sequences in the 5’ nontranslated region of hepatitis C virus required for RNA replication. J Virol 2001; 75: 12047-12057.

  24. Friebe P, Bartenschlager R. Genetic analysis of sequences in the 3’ nontranslated region of hepatitis C virus that are important for RNA replication. J Virol 2002; 76: 5326-5338.

  25. Tanaka T, Kato N, Cho MJ, Shimotohno K. A novel sequences found at the 3’ terminus of hepatitis C virus genome. Biochem Biophys Res Commun 1995; 215: 744-749.

  26. Kolykhalov AA, Feinstone SM, Rice CM. Identification of a highly conserved sequence element at the 3¢ terminus of hepatitis C virus genome RNA. J Virol 1996; 70: 3363-3371.

  27. Yanagi M, StClaire M, Emerson SU, Purcell RH, Bukh J. In vivo analysis of the 3¢ untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci USA 1999; 96: 2291-2295.

  28. Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. Nature 2002; 1: 911-916.

  29. Owsianka AM, Patel AH. Hepatitis C virus core protein interacts with a human DEAD box protein DDX3. Virology 1999; 257: 330: 340.

  30. Marusawa H, Hijikata M, Chiba T, Shimotohmo K. Hepatitis C virus core protein inhibits Fas-and tumor necrosis factor alpha mediated apoptosis via NF-kappa B activation. J Virol 1999; 73: 4713-4720.

  31. Ray RB, Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 2000; 271: 197-204.

  32. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997; 94: 1200-1205.

  33. Farci P, Shimoda A, Coiana A, Díaz G, Peddis G, Melpolder JC, Strazzera A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-344.

  34. Locarnini SA. Mechanism of drug resistance and novel approaches to therapy for chronic hepatitis C. J Gastroenterol Hepatol 2002; 17: S351-S359.

  35. Sanz-Cameno P, Borque MJ, García-Buey L, Moreno-Otero R. Interacción del virus de la hepatitis C con la membrana celular. Gastroenterol Hepatol 2002; 25: 521-525.

  36. Cocquerel L, Kuo CC, Dubuisson J, Levy S. CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol 2003; 19: 10677-10683.

  37. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon inducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-110.

  38. Sarrazin C, Kornetzky I, Ruster B, Lee JH, Kronenberger B, Bruch K, Roth WK, et al. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. Hepatology 2000; 31:1360-1370.

  39. Mihm S, Monazahiam M, Grethe S, Meier V, Thomssen R, Ramadori G. Lack of clinical evidence for involvement of hepatitis C virus interferon alpha sensitivity determining region variability in RNA dependent protein kinase mediated cellular antiviral responses. J Med Virol 2000; 61: 29-36.

  40. Francois C, Duverlie G, Reboulliat D, Khorsi H, Castelain S, Blum HE, Gatignol A, et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR mediated control of protein synthesis. J Virol 2000; 74: 5587-5596.

  41. Lesburg CA, Radfar RF, Weber PC. Recent advances in the analysis of HCV NS5B RNA dependent RNA polymerase. Curr Opin Investig Drugs 2000; 1: 289-296.

  42. Rivas-Estilla AM, Svitkin Y, López-Lastra M, Hatzoglou M, Sherker A, Koromilas AE. PKR dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone. J Virol 2002; 76: 10637-10653.

  43. Wang QM, Hockman MA, Staschke KF, Johnson RB, Case KA, Lu J, Parsons S, et al. Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA dependent RNA polymerase. J Virol 2002; 76: 3865-3872.

  44. Pavio N, Lai M. The hepatitis C virus persistente: how to evade the inmune system? J Biosci 2003; 28: 287-304.

  45. Iacovacci S, Sargiacomo M, Parolini I, Ponzetto A, Peschle C, Carloni G. Replication and multiplication of hepatitis C virus genome in human fetal liver cells. Res Virol 1993; 144: 275-279.

  46. Iacovacci S, Manzin A, Barca S, Sargiacomo M, Serafino A, Valli MB, Macioce G, et al. Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected in vitro. Hepatology 1997; 26: 1328-1337.

  47. Ito T, Mukaigawa J, Zuo J, Hirabayashi Y, Mitamura K, Yasui K. Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titles infectious virus. J Gen Virol 1996; 77: 1043-1054.

  48. Lanford RE, Sureau C, Jacob JR, White R, Fuerst TR. Demonstration of in vitro infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT/PCR. Virology 1994; 202: 606-614.

  49. Rumin S, Berthillon P, Tanaka E, Kiyosawak K, Trabaud MA, Bizollon T, Gouillat C, et al. Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J Gen Virol 1999; 80: 3007-3018.

  50. Cribier B, Schmitt C, Bingen A, Kirn A, Keller F. In vitro infection of peripheral blood mononuclear cells by hepatitis C virus. J Gen Virol 1995; 76: 2485-2491.

  51. Kato N, Ikeda M, Mizutani T, Sugiyamak K, Noguchi M, Hirohashi S, Shimotohno K. Replication of hepatitis C virus in cultured non-neoplastic human hepatocytes. Jpn J Cancer Res 1996; 87: 787-792.

  52. Ikeda M, Kato N, Mizutani T, Sugiyama K, Tanaka K, Shimotohno K. Analysis of the cell tropism of HCV by using in vitro HCV-infected human lymphocytes and hepatocytes. J Hepatol 1997; 27: 445-454.

  53. Ikeda M, Sugiyama K, Mizutani T, Tanaka T, Tanaka K, Sekihara H, Shimotohno K, et al. Human hepatocyte clonal cell lines that support persitent replication of hepatitis C virus. Virus Res 1998; 56: 157-167.

  54. Tawaga M, Kato N, Yokosuka O. Infection of human hepatocyte cell lines with hepatitis C virus in vitro. J Gastroenterol Hepatol 1995; 10: 523-527.

  55. Seipp S, Mueller HM, Pfaff E, Stremmel W, Theilmann L, Goeser T. Establishment of persistent hepatitis C virus infection and replication in vitro. J Gen Virol 1997; 78: 2467-2476.

  56. Clarysse C, Lin L, Crabbe T, Van Pelt JF, Cammack N, Yap SH. HVR1 quasispecies analysis from a long-term culture of hepatitis C virus in Hep G2 derived cells grown in a haemodialysis cartridge. J Viral Hepat 2001; 8: 132-138.

  57. Tsuboi S, Nagamori S, Miyasaki M, Mihara K, Fuyaka K, Teruya K, Kosaka T, et al. Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines. J Med Virol 1996; 48: 133-140.

  58. Yoshikura H, Hijikata M, Nakajima N, Mizuno K, Rikihisa T, Ueno T, et al. Correlation of in vivo infectivity of hepatitis C virus to in vitro infectivity and to virion properties. Princess Takamatsu Symp 1995; 25: 139-142.

  59. Nakajima N, Hijikata M, Yoshikura H, Shimizu YK. Characterization of long-term cultures of hepatitis C virus. J Virol 1996; 70: 3325-3329.

  60. Shimizu YK, Igarashi H, Kiyohara T, Shapiro M, Wong DC, Purcell RH, Yoshikura H. Infection of a chimpanzee with hepatitis C virus grown in cell culture. J Gen Virol 1998; 79: 1383-1386.

  61. Kato N, Nakazawa T, Mizutani T, Shimotohmo K. Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection. Biochem Biophys Res Commun 1995; 206: 863-869.

  62. Mizutani T, Kato N, Saito S, Ikeda M, Sugiyama K, Shimotohno K. Characterization of hepatitis C virus replication in cloned cells obtained from a human T-cell leukemia virus type 1- infected cell line, MT-2. J Virol 1996; 70: 7219-7223.

  63. Shimizu YK, Iwamoto A, Hijikata M, Purcell RH, Yoshikura H. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci USA 1992; 89: 5477-5481.

  64. Shimizu YK, Purcell RH, Yoshikura H. Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro. Proc Natl Acad Sci USA 1993; 6037-6041.

  65. Shimizu YK, Yoshikura H. Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons. J Virol 1994; 68: 8406-8408.

  66. Shimizu YK, Feinstone SM, Kohara M, Purcell RH, Yoshikura H. Hepatitis C virus: Detection of infracellular virus particles by electron microscopy. Hepatology 1996; 23: 205-209.

  67. Yoo BJ, Selby MJ, Choe J, Suh BS, Choi SH, Joh JS, Nuoro GJ, et al. Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro transcribed with HCV. J Virol 1995; 69: 32-38.

  68. Dash S, Halim AB, Tsuji H, Hiramatsu N, Gerber MA. Transfection of HepG2 cells with infectious hepatitis C virus genome. Am J Pathol 1997; 151: 363-373.

  69. Mercer D, Schiller D, Elliot J, Douglas DN, Hao C, Rinfret A, Addison WR, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933.

  70. Pietschmann T, Lohmann V, Rutter G, Kurpanek K, Bartenschlager R. Characterization of cell lines carrying self replicating hepatitis C virus RNAs. J Virol 2001; 75: 1252-1264.

  71. Krieger N, Lohmann V, Bastenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture adaptive mutations. J Virol 2001; 75: 4614-4624.

  72. Lohmann V, Körner F, Doblerzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001. 75; 1437-1449.

  73. Ikeda M, Yi M, Lemon SM. Selectable subgenomic and genome length bicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002; 76: 2997-3006.

  74. Pawlotsky JM. Mechanism of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Research 2003; 59: 1-11.

  75. Beckebaum S, Cicinnati VR, Gerken G. DNA-based immunotherapy: potential for treatment of chronic viral hepatitis?. Rev Med Virol 2002; 12: 297-319.

  76. Lamarre D, Anderson P, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-189.




2020     |     www.medigraphic.com